| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From Dipartimento di Fisiopatologia Clinica,*
Dipartimento di Scienze Biomediche ed
Oncologia,
and Dipartimento di Discipline
Medico-Chirurgiche,
Università di
Torino, Italy; 3S-Pharmacological Consultation and Research
GmbH,§
Harpstedt, Germany; and Cattedra di
Nefrologia,¶
Dipartimento di Scienze Cliniche e
Biologiche, II Facoltà di Medicina e Chirurgia, Università
di Pavia, Varese, Italy
This study investigated the presence of platelet-activating factor (PAF) in the lipid extracts of 18 primary breast carcinomas and 20 control breast tissues. The amount of PAF detected in breast carcinomas was significantly higher than in controls. The mass spectrometric analysis of PAF-bioactive lipid extract from breast carcinomas showed the presence of several molecular species of PAF, including C16-alkylPAF, C18-lysophosphatidylcholine (LPC), C16-LPC, lyso-PAF, and C16-acylPAF. The amount of bioactive PAF extracted from breast specimens significantly correlated with tumor vascularization revealed by the number of CD34- and CD31-positive cells. As C16-alkylPAF was previously shown to induce angiogenesis in vivo, we evaluated whether the thin layer chromatography-purified lipid extracts of breast specimens elicited neoangiogenesis in a murine model of subcutaneous Matrigel injection. The lipid extracts from specimens of breast carcinoma containing high levels of PAF bioactivity, but not from breast carcinomas containing low levels of PAF bioactivity or from normal breast tissue, induced a significant angiogenic response. This angiogenic response was significantly inhibited by the PAF receptor antagonist WEB 2170. T47D and MCF7 breast cancer cell lines, but not an immortalized nontumor breast cell line (MCF10), released PAF in the culture medium. A significant in vivo neoangiogenic response, inhibited by WEB 2170, was elicited by T47D and MCF7 but not by MCF10 culture medium. These results indicate that an increased concentration of PAF is present in tumors with high microvessel density and that PAF may account for the neoangiogenic activity induced in mice by the lipid extracts obtained from breast cancer. A contribution of PAF in the neovascularization of human breast cancer is suggested.
This article has been cited by other articles:
 |
|
 |
|
  J. Si, J. Behar, J. Wands, D. G. Beer, D. Lambeth, Y. Eugene Chin, and W. Cao STAT5 mediates PAF-induced NADPH oxidase NOX5-S expression in Barrett's esophageal adenocarcinoma cells Am J Physiol Gastrointest Liver Physiol, January 1, 2008; 294(1): G174 - G183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Doublier, M. Ceretto, E. Lupia, S. Bravo, B. Bussolati, and G. Camussi The Proangiogenic Phenotype of Tumor-Derived Endothelial Cells is Reverted by the Overexpression of Platelet-Activating Factor Acetylhydrolase Clin. Cancer Res., October 1, 2007; 13(19): 5710 - 5718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Heon Seo, H.-M. Ko, H.-A Kim, J.-H. Choi, S. Jun Park, K.-J. Kim, H.-K. Lee, and S.-Y. Im Platelet-Activating Factor Induces Up-regulation of Antiapoptotic Factors in a Melanoma Cell Line through Nuclear Factor-{kappa}B Activation. Cancer Res., May 1, 2006; 66(9): 4681 - 4686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Denizot, T. Chianea, F. Labrousse, V. Truffinet, M. Delage, and M. Mathonnet Platelet-activating factor and human thyroid cancer Eur. J. Endocrinol., July 1, 2005; 153(1): 31 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Owen, R. L. Wykle, M. P. Samuel, and M. J. Thomas An improved assay for platelet-activating factor using HPLC-tandem mass spectrometry J. Lipid Res., February 1, 2005; 46(2): 373 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Ma, P. Ottino, H. E. P. Bazan, and N. G. Bazan Platelet-Activating Factor (PAF) Induces Corneal Neovascularization and Upregulates VEGF Expression in Endothelial Cells Invest. Ophthalmol. Vis. Sci., September 1, 2004; 45(9): 2915 - 2921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Biancone, V. Cantaluppi, L. Del Sorbo, S. Russo, L. W. Tjoelker, and G. Camussi Platelet-activating Factor Inactivation by Local Expression of Platelet-activating Factor Acetyl-Hydrolase Modifies Tumor Vascularization and Growth Clin. Cancer Res., September 15, 2003; 9(11): 4214 - 4220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Seike, T. Kondo, Y. Mori, A. Gemma, S. Kudoh, M. Sakamoto, T. Yamada, and S. Hirohashi Proteomic Analysis of Intestinal Epithelial Cells Expressing Stabilized {beta}-Catenin Cancer Res., August 1, 2003; 63(15): 4641 - 4647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Deo, T. W. Axelrad, E. G. Robert, V. Marcheselli, N. G. Bazan, and J. D. Hunt Phosphorylation of STAT-3 in Response to Basic Fibroblast Growth Factor Occurs through a Mechanism Involving Platelet-activating Factor, JAK-2, and Src in Human Umbilical Vein Endothelial Cells. EVIDENCE FOR A DUAL KINASE MECHANISM J. Biol. Chem., June 7, 2002; 277(24): 21237 - 21245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-M. Ko, K. H. Seo, S.-J. Han, K. Y. Ahn, I.-H. Choi, G. Y. Koh, H.-K. Lee, M. S. Ra, and S.-Y. Im Nuclear Factor {kappa}B Dependency of Platelet-activating Factor-induced Angiogenesis Cancer Res., March 1, 2002; 62(6): 1809 - 1814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Brocheriou, D. Stengel, L. Mattsson-Hulten, J. Stankova, M. Rola-Pleszczynski, F. Koskas, O. Wiklund, Y. Le Charpentier, and E. Ninio Expression of Platelet-Activating Factor Receptor in Human Carotid Atherosclerotic Plaques : Relevance to Progression of Atherosclerosis Circulation, November 21, 2000; 102(21): 2569 - 2575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Bussolati, L. Biancone, P. Cassoni, S. Russo, M. Rola-Pleszczynski, G. Montrucchio, and G. Camussi PAF Produced by Human Breast Cancer Cells Promotes Migration and Proliferation of Tumor Cells and Neo-Angiogenesis Am. J. Pathol., November 1, 2000; 157(5): 1713 - 1725. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
